Clinical Trials Browser

Anemia, Aplastic, Autoimmune Diseases, Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Phase 2 Active not recruiting

401 enrolled

Plasma cell

Disease, Multiple Myeloma

NCT01857115 2024-11-13

wCCyd

Phase 1/2 Completed

63 enrolled

Plasma cell

Disease, Multiple Myeloma

NCT01190787 2024-01-23

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

Phase 2 Completed

150 enrolled

Plasma cell

Disease, Multiple Myeloma

NCT02204241 2023-07-03

CCD

Phase 1/2 Completed

36 enrolled

Plasma cell

Disease, Multiple Myeloma

NCT02022579 2018-10-11

ACRIN6702

Phase NA Unknown

100 enrolled

Breast

Breast Neoplasms, Disease

Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

wCCyd

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

CCD

ACRIN6702